Quest Diagnostics enters its July 21 earnings window with short sellers quietly retreating and options traders leaning more bullish than usual — a modest but consistent tilt toward the constructive side heading into the next print.
The clearest positioning signal right now is the slow bleed in short interest. Bears have trimmed exposure by roughly 3.3% over the past month, bringing the short position to 3.2% of the free float — a level that simply isn't large enough to drive the narrative on its own. What makes the lending picture more interesting is the cost-to-borrow trend: despite the modest short position, borrowing costs have risen about 21% over the week to 0.53%. That's still low in absolute terms, but the direction of travel is notable given that availability remains extremely loose — with roughly 1,365 shares available to borrow for every 100 already lent out, there's no shortage of supply. The CTB move looks more like routine fluctuation than any building squeeze pressure.
Options positioning adds a modestly bullish tilt to that picture. The put/call ratio has eased to 0.76, sitting below its 20-day average of 0.81 and about 0.8 standard deviations below the mean. That's not an extreme reading, but it does suggest call activity has edged ahead of put hedging relative to the recent norm — a contrast to the more defensive 0.93–0.95 range that dominated through late May. The PCR 52-week low of 0.42 shows there's room for calls to extend further, while the 52-week high of 1.38 frames just how defensive the market can get on this name when sentiment sours.
The Street picture is constructive but measured. The most recent analyst actions, clustered around the April 21 earnings release, saw multiple firms raise price targets — UBS moved to $220 from $210, Barclays to $230 from $225, and Truist to $225 from $220 — while holding neutral or overweight ratings. The consensus mean target of $223 implies roughly 13% upside from the current $197.18 price, though the most recent target adjustments are now two months old and may not fully reflect the intervening price move. The bull case rests on the 7.1% revenue growth to $2.81 billion and the consumer-initiated testing platform's 35% expansion, which contributed nearly $250 million in revenue. Bears counter with declining revenue per requisition from key accounts including Corewell and Fresenius, and the expectation that 2026 pricing will flatten. The dividend factor score ranks in the 98th percentile, signalling income investors remain well-served, though forward EPS momentum trails — the 12-month forward EPS year-on-year increase scores just 34th percentile, suggesting the growth narrative has limits at current multiples. The P/E of 17.4x has drifted down modestly over the past week, while EV/EBITDA of 11.5x has also slipped slightly, keeping valuation in a reasonable range rather than stretched territory.
Closest peer LH tracked DGX almost tick-for-tick on the week, both down roughly 2% compared to a 1.9% weekly decline for DGX — confirmation that the softness is sector-wide rather than stock-specific. Insiders have been net sellers, with the CEO offloading 10,000 shares at $194.14 on June 1 and a Senior Vice President selling 8,147 shares at $200 on June 4, generating a combined $3.6 million in net sales over the 90-day window. The significance scores on both transactions were low, and the trades followed equity award grants in March, so the selling reads more as routine liquidity management than a directional view on the business.
With Q2 results scheduled for July 21, the setup to watch is whether the consumer-initiated testing platform can sustain its growth trajectory against a backdrop of flat pricing — the revenue-per-requisition trend is the metric most likely to set the tone for how the Street responds on the day.
See the live data behind this article on ORTEX.
Open DGX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
